A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon:
MOSAIC
MOSAIC Stage ll+lll FOLFOX4 LV5FU2 Randomize. DFS DFS (months) Hazard ratio: 0.77 [0.65 – 0.92] p < 0.01 FOLFOX (n=1123) 77.9% LV5FU2 (n=1123) 72.8% FOLFOX.
![MOSAIC Stage ll+lll FOLFOX4 LV5FU2 Randomize. DFS DFS (months) Hazard ratio: 0.77 [0.65 – 0.92] p < 0.01 FOLFOX (n=1123) 77.9% LV5FU2 (n=1123) 72.8% FOLFOX.](https://static.fdocuments.us/doc/330x215/56649cac5503460f9496e2a1/mosaic-stage-lllll-folfox4-lv5fu2-randomize-dfs-dfs-months-hazard-ratio.jpg)
